Loading...

David Straus

Title(s)Associate Physician, Surgery
SchoolHealth Sciences
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero A, Gallamini A. Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020 Jan 16. PMID: 31945149.
      View in: PubMed
    2. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano JF, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Luminari S, Marcheselli L, Federico M, Younes A. Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020 Jan 08; 126:78-90. PMID: 31927165.
      View in: PubMed
    3. Sarlo KM, Dixon BN, Ni A, Straus DJ. Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody. Leuk Lymphoma. 2019 Oct 11; 1-6. PMID: 31603363.
      View in: PubMed
    4. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019 Oct 10; 134(15):1238-1246. PMID: 31331918.
      View in: PubMed
    5. Lee Chuy K, Nahhas O, Dominic P, Lopez C, Tonorezos E, Sidlow R, Straus D, Gupta D. Cardiovascular Complications Associated with Mediastinal Radiation. Curr Treat Options Cardiovasc Med. 2019 Jun 04; 21(7):31. PMID: 31161453.
      View in: PubMed
    6. Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD, Younes A. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019 05 20; 9(6):50. PMID: 31110172.
      View in: PubMed
    7. Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 05 16; 133(20):2121-2129. PMID: 30770396.
      View in: PubMed
    8. Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clin Cancer Res. 2019 03 15; 25(6):1718-1726. PMID: 30617130.
      View in: PubMed
    9. Bonafede M, Feliciano J, Cai Q, Noxon V, Princic N, Richhariya A, Straus DJ. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. Clinicoecon Outcomes Res. 2018; 10:629-641. PMID: 30410373.
      View in: PubMed
    10. Amundson JR, Straus D, Azab B, Liu S, Garcia Buitrago MT, Yakoub D. Giant symptomatic gastric lipoma: A case report and literature review. Int J Surg Case Rep. 2018; 51:313-317. PMID: 30245352.
      View in: PubMed
    11. Straus DJ. Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity. Cancer J. 2018 Sep/Oct; 24(5):223-229. PMID: 30247257.
      View in: PubMed
    12. Brito da Silva H, Straus D, Barber JK, Rostomily RC, Ferreira M, Sekhar LN. Cranial Chordoma: A New Preoperative Grading System. Neurosurgery. 2018 09 01; 83(3):403-415. PMID: 29126120.
      View in: PubMed
    13. Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018 09 06; 132(10):1013-1021. PMID: 30049811.
      View in: PubMed
    14. Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J. 2018 06 12; 8(6):60. PMID: 29895903.
      View in: PubMed
    15. Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018 04 19; 131(16):1805-1808. PMID: 29386196.
      View in: PubMed
    16. Straus DJ. Initial Hodgkin treatment of the frail elderly. Blood. 2017 12 28; 130(26):2813-2814. PMID: 29284610.
      View in: PubMed
    17. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 01 25; 378(4):331-344. PMID: 29224502.
      View in: PubMed
    18. Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017 11 16; 130(20):2196-2203. PMID: 28874350.
      View in: PubMed
    19. Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 01; 23(15):4119-4126. PMID: 28314788.
      View in: PubMed
    20. Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 09 15; 128(11):1458-64. PMID: 27458003.
      View in: PubMed
    21. Qureshi T, Chaus F, Fogg L, Dasgupta M, Straus D, Byrne RW. Learning curve for the transsphenoidal endoscopic endonasal approach to pituitary tumors. Br J Neurosurg. 2016 Dec; 30(6):637-642. PMID: 27332969.
      View in: PubMed
    22. Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 06 10; 34(17):2020-7. PMID: 27069074.
      View in: PubMed
    23. Straus DJ, Cahlon O. Radiation Therapy for Hodgkin Lymphoma--Can It Be Administered More Safely if Necessary? JAMA Oncol. 2016 Feb; 2(2):169-70. PMID: 26606467.
      View in: PubMed
    24. Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. J Nucl Med. 2016 May; 57(5):728-34. PMID: 26719374.
      View in: PubMed
    25. Lopes DK, Moftakhar R, Straus D, Munich SA, Chaus F, Kaszuba MC. Arteriovenous malformation embocure score: AVMES. J Neurointerv Surg. 2016 Jul; 8(7):685-91. PMID: 26078359.
      View in: PubMed
    26. Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. J Natl Cancer Inst. 2015 Apr; 107(4). PMID: 25717170.
      View in: PubMed
    27. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar; 16(3):284-92. PMID: 25683846.
      View in: PubMed
    28. Straus DJ, Hamlin PA, Matasar MJ, Lia Palomba M, Drullinsky PR, Zelenetz AD, Gerecitano JF, Noy A, Hamilton AM, Elstrom R, Wegner B, Wortman K, Cella D. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. Br J Haematol. 2015 Mar; 168(5):663-70. PMID: 25316653.
      View in: PubMed
    29. Gerard CS, Straus D, Byrne RW. Surgical management of low-grade gliomas. Semin Oncol. 2014 Aug; 41(4):458-467. PMID: 25173139.
      View in: PubMed
    30. Straus DJ. Radiotherapy should be omitted in most patients. Clin Adv Hematol Oncol. 2014 Apr; 12(4):247-9. PMID: 25134171.
      View in: PubMed
    31. Crandall M, Sharp D, Unger E, Straus D, Brasel K, Hsia R, Esposito T. Trauma deserts: distance from a trauma center, transport times, and mortality from gunshot wounds in Chicago. Am J Public Health. 2013 Jun; 103(6):1103-9. PMID: 23597339.
      View in: PubMed
    32. Deng G, Chan Y, Sjoberg D, Vickers A, Yeung KS, Kris M, Straus D, Cassileth B. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Support Care Cancer. 2013 Jun; 21(6):1735-41. PMID: 23334562.
      View in: PubMed
    33. Vijai J, Kirchhoff T, Schrader KA, Brown J, Dutra-Clarke AV, Manschreck C, Hansen N, Rau-Murthy R, Sarrel K, Przybylo J, Shah S, Cheguri S, Stadler Z, Zhang L, Paltiel O, Ben-Yehuda D, Viale A, Portlock C, Straus D, Lipkin SM, Lacher M, Robson M, Klein RJ, Zelenetz A, Offit K. Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet. 2013; 9(1):e1003220. PMID: 23349640.
      View in: PubMed
    34. Moskowitz AJ, Hamlin PA, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013 Feb 01; 31(4):456-60. PMID: 23248254.
      View in: PubMed
    35. Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed. 2012 Oct; 28(5):250-7. PMID: 22971190.
      View in: PubMed
    36. Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov; 53(11):2143-50. PMID: 22421007.
      View in: PubMed
    37. Cooper RA, Straus DJ. Clinical guidelines, the politics of value, and the practice of medicine: physicians at the crossroads. J Oncol Pract. 2012 Jul; 8(4):233-5. PMID: 23180988.
      View in: PubMed
    38. Aliaga L, Hekman KE, Yassari R, Straus D, Luther G, Chen J, Sampat A, Frim D. A novel scoring system for assessing Chiari malformation type I treatment outcomes. Neurosurgery. 2012 Mar; 70(3):656-64; discussion 664-5. PMID: 21849925.
      View in: PubMed
    39. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Straus DJ. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. J Am Acad Dermatol. 2012 Nov; 67(5):867-75. PMID: 22285675.
      View in: PubMed
    40. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schoder H, Yahalom J. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012 Feb 16; 119(7):1665-70. PMID: 22184409.
      View in: PubMed
    41. Straus DJ. Chemotherapy alone for early-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 02; 366(5):470-1. PMID: 22149920.
      View in: PubMed
    42. Straus DJ. Recent results of treatment of early stage Hodgkin lymphoma: risk-adapted approaches. Leuk Lymphoma. 2011 May; 52(5):738-9. PMID: 21504296.
      View in: PubMed
    43. Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient. Ther Adv Hematol. 2011 Apr; 2(2):111-9. PMID: 23556081.
      View in: PubMed
    44. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20. PMID: 21355087.
      View in: PubMed
    45. Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res. 2011 Apr 15; 17(8):2493-501. PMID: 21346146.
      View in: PubMed
    46. Balagula Y, Straus DJ, Pulitzer MP, Lacouture ME. Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia. J Clin Oncol. 2011 Apr 10; 29(11):e305-7. PMID: 21245419.
      View in: PubMed
    47. Czuczman M, Straus D, Gribben J, Bredenfeld H, Friedberg J, Bollard C. Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leuk Lymphoma. 2010 Aug; 51 Suppl 1:41-9. PMID: 20658953.
      View in: PubMed
    48. Straus DJ. Primary thyroid lymphoma, a rare disease with a good treatment outcome. J Surg Oncol. 2010 Jun 01; 101(7):543-4. PMID: 20461758.
      View in: PubMed
    49. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010 Apr 10; 28(11):1896-903. PMID: 20212248.
      View in: PubMed
    50. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10; 28(11):1870-7. PMID: 20212249.
      View in: PubMed
    51. Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, Kewalramani T, Moskowitz AJ, Rice RD, Maragulia J, Vanak J, Trippett T, Hamlin P, Horowitz S, Noy A, O'Connor OA, Portlock C, Straus D, Nimer SD. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010 Mar; 148(6):890-7. PMID: 20085577.
      View in: PubMed
    52. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Mac-Gregor Cortelli B, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, Vose J. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010 Jan 15; 16(2):719-26. PMID: 20068103.
      View in: PubMed
    53. Straus DJ. The case for chemotherapy only for localized Hodgkin lymphoma. Oncologist. 2009 Dec; 14(12):1225-31. PMID: 20007643.
      View in: PubMed
    54. Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O'Connor OA. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol. 2009 Sep; 146(6):652-5. PMID: 19624539.
      View in: PubMed
    55. O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol. 2009 Apr; 145(1):34-9. PMID: 19220284.
      View in: PubMed
    56. O'Connor OA, Portlock C, Moskowitz C, Straus D, Hamlin P, Stubblefield M, Dumetrescu O, Colevas AD, Grant B, Zelenetz A. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2008 Oct; 143(2):201-9. PMID: 18691173.
      View in: PubMed
    57. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008 Jan; 14(1):59-66. PMID: 18158962.
      View in: PubMed
    58. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, Mould DR, Fleischer M, Zelenetz AD, Sirotnak F, Horwitz S. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol. 2007 Nov; 139(3):425-8. PMID: 17910632.
      View in: PubMed
    59. Straus DJ. How I treat mantle cell lymphoma. J Oncol Pract. 2007 Sep; 3(5):281-2. PMID: 20859426.
      View in: PubMed
    60. Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 01; 109(9):1799-803. PMID: 17366595.
      View in: PubMed
    61. Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006 Oct 15; 107(8):1909-17. PMID: 16977654.
      View in: PubMed
    62. Straus DJ. Treatment of early-stage nonbulky Hodgkin lymphoma. Curr Opin Oncol. 2006 Sep; 18(5):432-6. PMID: 16894289.
      View in: PubMed
    63. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006 Aug; 47(8):1326-34. PMID: 16883013.
      View in: PubMed
    64. Portlock CS, O'Connor OA, Straus DJ, Rosenzweig L, Dumitrescu O, Lin O, Maslak P. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation? Leuk Lymphoma. 2006 Jul; 47(7):1260-4. PMID: 16923555.
      View in: PubMed
    65. Straus DJ. Management of anemia in patients with hematologic malignancies. Oncology (Williston Park). 2006 Jul; 20(8 Suppl 6):8-11. PMID: 16925104.
      View in: PubMed
    66. Gerecitano J, Straus DJ. Treatment of Burkitt lymphoma in adults. Expert Rev Anticancer Ther. 2006 Mar; 6(3):373-81. PMID: 16503854.
      View in: PubMed
    67. Straus DJ. Management of early stage Hodgkin's lymphoma. Cancer Treat Res. 2006; 131:317-32. PMID: 16704174.
      View in: PubMed
    68. Straus D. Comparative studies on erythropoietic agents. J Natl Compr Canc Netw. 2005 Nov; 3 Suppl 1:S46-9. PMID: 16280113.
      View in: PubMed
    69. Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005 Sep; 130(5):691-9. PMID: 16115124.
      View in: PubMed
    70. Straus DJ. Treatment of anemia with erythropoietic agents in patients with hematologic malignancies. Support Cancer Ther. 2005 Jul 01; 2(4):215-24. PMID: 18628176.
      View in: PubMed
    71. Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, O'Connor OA, Yahalom J, Zelenetz AD. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma. 2005 Apr; 46(4):541-7. PMID: 16019482.
      View in: PubMed
    72. Straus DJ. HIV-associated lymphoma: promising new results, but with toxicity. Blood. 2005 Mar 01; 105(5):1842. PMID: 15747398.
      View in: PubMed
    73. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):676-84. PMID: 15613699.
      View in: PubMed
    74. O'Connor O, Wright J, Moskowitz CH, Muzzy J, MacGregor-Cortelli B, Hamlin P, Straus D, Trehu E, Schenkein DP, Zelenetz AD. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. J Natl Compr Canc Netw. 2004 Nov; 2 Suppl 4:S21-2. PMID: 19791425.
      View in: PubMed
    75. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 01; 104(12):3483-9. PMID: 15315964.
      View in: PubMed
    76. Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, Noy A, O'Connor O, Horwitz S, Moskowitz C, Filippa DA. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004 Jun; 125(6):701-8. PMID: 15180859.
      View in: PubMed
    77. Vickers AJ, Straus DJ, Fearon B, Cassileth BR. Acupuncture for postchemotherapy fatigue: a phase II study. J Clin Oncol. 2004 May 01; 22(9):1731-5. PMID: 15117996.
      View in: PubMed
    78. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 May 15; 103(10):3684-8. PMID: 14739217.
      View in: PubMed
    79. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003 Sep 15; 98(6):1196-205. PMID: 12973843.
      View in: PubMed
    80. Straus DJ. Epoetin alfa therapy for patients with hematologic malignancies and mild anemia. Clin Lymphoma. 2003 Aug; 4 Suppl 1:S13-7. PMID: 14556671.
      View in: PubMed
    81. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003 Sep 15; 102(6):1989-96. PMID: 12676776.
      View in: PubMed
    82. Straus DJ. Gallium nitrate in the treatment of lymphoma. Semin Oncol. 2003 Apr; 30(2 Suppl 5):25-33. PMID: 12776257.
      View in: PubMed
    83. Straus DJ. Epoetin alfa as a supportive measure in hematologic malignancies. Semin Hematol. 2002 Oct; 39(4 Suppl 3):25-31. PMID: 12447849.
      View in: PubMed
    84. Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J. 2002 Sep-Oct; 8(5):371-6. PMID: 12416894.
      View in: PubMed
    85. Niesvizky R, Siegel D, Glassman J, Straus D, Fine J, Lyons L, Michaeli J. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leuk Lymphoma. 2002 Mar; 43(3):607-12. PMID: 12002766.
      View in: PubMed
    86. Straus DJ. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res. 2002; 159:143-8. PMID: 11785838.
      View in: PubMed